Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia

Leukemia

Volumn 19, Issue 7, 2005, Pages 1207-1210

  Lin, T S ^a   Flinn, I W ^b   Lucas, M S ^a   Porcu, P ^a   Sickler, J ^b   Moran, M E ^a   Lucas, D M ^a   Heerema, N A ^a   Grever, M R ^a   Byrd, J C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Alemtuzumab; CLL; CMV; Cytomegalovirus; Filgrastim; G CSF

Indexed keywords

ALEMTUZUMAB; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER SIZE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LYMPH NODE METASTASIS; MALE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; VIRUS REACTIVATION;

EID: 21744442455     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403782     Document Type: Article

References (8)

1. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873-882.
2. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000; 12: 574-581.
3. Keating MJ, Flinn I, Jain V, Binet J-L, Hillmen P, Byrd JC et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.
4. Mazzulli T, Drew LW, Yen-Lieberman B, Jekic-McMullen D, Kohn DJ, Isada C et al. Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia. J Clin Microbiol 1999; 37: 958-963.
5. Byrd JC, Smith L, Hackbarth ML, Flinn IW, Young D, Proffitt JH et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003; 63: 36-38.
6. Cheson BD, Bennett JM, Grever MR, Kay NE, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
7. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K et al. Common toxicity criteria: version 2.0 an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13-47.
8. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.